Provided by Tiger Trade Technology Pte. Ltd.

Kura Oncology

11.89
+0.18001.54%
Post-market: 11.900.0100+0.08%19:54 EDT
Volume:2.03M
Turnover:24.18M
Market Cap:1.06B
PE:-3.53
High:12.25
Open:11.78
Low:11.67
Close:11.71
52wk High:12.90
52wk Low:7.36
Shares:88.77M
Float Shares:70.60M
Volume Ratio:0.71
T/O Rate:2.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3668
EPS(LYR):-3.1784
ROE:-167.71%
ROA:-31.30%
PB:21.79
PE(LYR):-3.74

Loading ...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Kura Oncology Price Target Maintained With a $24.00/Share by Citizens

Dow Jones
·
Jun 15

Wedbush Remains a Buy on Kura Oncology (KURA)

TIPRANKS
·
Jun 15

Analysts’ Top Healthcare Picks: MBX Biosciences, Inc. (MBX), Kura Oncology (KURA)

TIPRANKS
·
Jun 13

Kura Oncology posts EHA investor deck detailing ziftomenib AML clinical update

Reuters
·
Jun 12

BUZZ-Kura Oncology up as leukemia drug shows strong survival in early- to mid-stage trial

Reuters
·
Jun 11

Kura Oncology, Kyowa Kirin Cancer Combo Therapy Extends Survival in AML Patients

MT Newswires Live
·
Jun 11

Kura Oncology reports 94% 12-month survival in KOMET-007 trial of ziftomenib plus 7+3 in newly diagnosed NPM1-mutant AML

Reuters
·
Jun 11

Kura Oncology - Ziftomenib 600 Mg Once-Daily Plus 7+3 Well Tolerated With No New Safety Signals

THOMSON REUTERS
·
Jun 11

Kura Oncology and Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination in Newly Diagnosed Aml

THOMSON REUTERS
·
Jun 11

Kura Oncology - Reports 12-Month Os Rate of 94% in Npm1-M Aml, 71% in Kmt2a-R Aml

THOMSON REUTERS
·
Jun 11

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

GlobeNewswire
·
Jun 11

Analysts Conflicted on These Healthcare Names: Aveanna Healthcare Holdings (AVAH), Kura Oncology (KURA) and Hyperion DeFi (HYPD)

TIPRANKS
·
Jun 08

Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer

TIPRANKS
·
Jun 06

Kura Oncology grants 53,000 inducement stock options at $9.04 per share

Reuters
·
Jun 05

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 05

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 05

Lake Street Initiates a Buy Rating on Kura Oncology (KURA)

TIPRANKS
·
Jun 05

Kura Oncology Shareholders Approve Expanded Equity Incentive Plans

TIPRANKS
·
Jun 05

Kura Oncology expands 2014 equity incentive plan share reserve to 41,077,686 shares

Reuters
·
Jun 05